Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

S&P 500 Gives Up Gains as Tech Bid Loses Steam

Published 05/10/2022, 02:47 PM
Updated 05/10/2022, 03:55 PM
© Reuters

© Reuters

By Yasin Ebrahim

Investing.com -- The S&P 500 gave up some gains Tuesday, as global growth concerns continued to weigh on sentiment, while the rebound in tech lost some steam into the close a day ahead of fresh U.S. inflation data. 

The S&P 500 rose 0.1%, the Dow Jones Industrial Average fell 0.4%, or 130 points, the Nasdaq rallied 0.9%.

Tech rallied as dip-buying action returned, underpinned by a fall in Treasury yields.

Microsoft (NASDAQ:MSFT) and Alphabet (NASDAQ:GOOGL) led the gains in big tech, both rising more than 1%. Facebook (NASDAQ:FB), and Apple (NASDAQ:AAPL) were above the flatline. While Amazon (NASDAQ:AMZN) was flat. 

The 10-year Treasury yield fell further below 3%, a day ahead of fresh U.S. inflation data expected to show slowing price pressures that could bolster investor sentiment stocks.  

“Investors are looking for signs of a potential ‘peak’ in the inflationary pressures we have encountered over the last several months- and if they get a hint of anything close, the markets could be set to stage a strong rally in our view,” Janney Montgomery Scott said in a note.

Peloton Interactive (NASDAQ:PTON), meanwhile, cut some losses to trade 9% lower as the connected equipment fitness company delivered guidance that fell short of estimates after reporting a wider loss than expected in the third quarter. The stock had been down more than 20% intraday. 

“Our Q4 outlook reflects softer demand vs. our February forecast,” Peloton said, adding that its subscription price hike had led to an increase in cancellations, but the impact was expected to be “modest.”

AMC Entertainment Inc (NYSE:AMC) fell more than 6% even as the movie chain operator reported quarterly results that beat on both the top and bottom lines as box office hits including “The Batman,” spurred a return to the big screen for moviegoers.

Health care stocks were boosted by a 4% jump in Biogen (NASDAQ:BIIB) after the drugmaker made further progress toward the potential approval of its proposed Alzheimer's disease drug lecanemab.

Biogen and Eisai submitted a rolling drug Biologics License Application for lecanemab that could, depending on the outcome of an ongoing confirmatory late-stage clinical study, pave the way for the companies to apply for full approval of the drug later this year.

Novavax (NASDAQ:NVAX) cut losses to trade more than 1% higher despite reporting quarterly results that fell short of Wall Street estimates.

Energy stocks shrugged off a decline in oil prices as intensifying lockdown measures in Shanghai continued to stoke fears about demand. “[T]he strict zero-Covid strategy in China is putting the brakes on oil demand there,” Commerzbank said in a note.

Latest comments

Another joke of a day in the laughingstock of the investing world.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.